Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E.
Buy
Sell